Article

A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma.

Department of Oncology, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy.
Cancer Chemotherapy and Pharmacology (impact factor: 2.83). 10/2008; 62(4):673-8. DOI:10.1007/s00280-007-0653-y pp.673-8
Source: PubMed

ABSTRACT Limited information on second-line treatment in patients with pancreatic adenocarcinoma is available. At time of first-line treatment failure, approximately half of the patients are candidates for further treatment.
A retrospective review of 183 patients submitted to second-line therapy has been performed to identify prognostic factors, provides useful information for patients counseling and generates hypotheses for future studies. Inclusion criteria were: cytological or histologic diagnosis of pancreatic adenocarcinoma and prior gemcitabine-including chemotherapy. Any age, performance status (PS) and chemotherapy regimen were considered.
One hundred and eighty-three patients (106 males; 168 metastatic; median age 62 years; median PS 1; 63 submitted to prior curative surgery, 32 to prior radiotherapy) with a median previous progression-free survival (PFS) of 6.7 months were included. Median and 6-month PFS after initiation of salvage therapy were 3.0 months and 20%. Median, 1 and 2 years, overall survival after initiation of salvage therapy were 6.2 months, 17 and 4%, respectively. Previous PFS, CA19.9 levels and age independently predicted OS.
Re-challenge with gemcitabine and 5-fluorouracil administration may have a role in selected patients.

0 0
 · 
0 Bookmarks
 · 
38 Views
  • Source
    Article: Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).
    Mariacristina Di Marco, Roberto Di Cicilia, Marina Macchini, Elisabetta Nobili, Silvia Vecchiarelli, Giovanni Brandi, Guido Biasco
    [show abstract] [hide abstract]
    ABSTRACT: Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world. Surgery remains the only treatment offering an advantage in terms of overall survival (5-year survival range, 15-25%), but unfortunately only 10-20% of patients present resectable disease at the time of diagnosis. Hence chemotherapy, possibly combined with radiation therapy, remains the only treatment option aimed at palliation of symptoms and ensuring a better quality of life. Notwithstanding the efforts to find more effective therapies for the treatment of pancreatic cancer, significant results have not yet been achieved. Increasing interest has focused on integrated treatments, i.e. chemotherapy combined with targeted therapies, and a better selection of patients. This study examines the principal clinical trials that will help give clinicians an overview of the progress made in the systemic therapy for advanced pancreatic cancer patients in recent years.
    Oncology Reports 05/2010; 23(5):1183-92. · 1.84 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

168 metastatic
 
2 years
 
5-fluorouracil administration
 
6-month PFS
 
first-line treatment failure
 
future studies
 
histologic diagnosis
 
Limited information
 
median age 62 years
 
median previous progression-free survival
 
median PS 1
 
pancreatic adenocarcinoma
 
prior curative surgery
 
prior gemcitabine-including chemotherapy
 
prognostic factors
 
PS
 
Re-challenge
 
salvage therapy
 
second-line treatment
 
useful information